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Available online 6 February 2019Background: The V-ATPase proton pump controls acidiﬁcation of intra and extra-cellular milieu in both physio-
logical and pathological conditions. We previously showed that some V-ATPase subunits are enriched in glioma
stem cells and in patients with poor survival. In this study, we investigated how expression of a GBM-like
V-ATPase pump inﬂuences the non-neoplastic brain microenvironment.
Methods: Large oncosome (LO) vesicleswere isolated from primary glioblastoma (GBM) neurospheres, or frompa-
tient sera, and co-culturedwith primary neoplastic or non-neoplastic brain cells. LO transcript and protein contents
wereanalyzedbyqPCR, immunoblottingand immunogoldstaining.Activationofpathways in recipient cellswasde-
terminedat gene andprotein expression levels. V-ATPase activitywas impairedbyBaﬁlomycinA1or gene silencing.
Findings:GBM neurospheres inﬂuence their non-neoplastic microenvironment by delivering the V-ATPase subunit
V1G1 and the homeobox genes HOXA7, HOXA10, and POU3F2 to recipient cells via LO. LOs reprogram recipient
cells to proliferate, grow as spheres and to migrate. Moreover, LOs are particularly abundant in the circulation of
GBM patients with short survival time. Finally, impairment of V-ATPase reduces LOs activity.
Interpretation:We identiﬁed a novel mechanism adopted by glioma stem cells to promote disease progression via
LO-mediated reprogramming of their microenvironment. Our data provide preliminary evidence for future devel-
opment of LO-based liquid biopsies and suggest a novel potential strategy to contrast glioma progression.
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Glioblastoma (GBM) is a very aggressive form of malignant brain
tumor and one of the least treatable cancers. One of themost important
enabling features of GBMs is the ability to subvert the normal tissue19.01.052.
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. This is an open access article underenvironment to supply their growth needs [1]. In principle, a deep un-
derstanding of themeans bywhich the tumor reprograms its surround-
ings could prompt development of new drugs or treatments to slow
down, and eventually eradicate, the disease.
The ability of a tumor to modify its microenvironment is a major
hallmark of malignant progression [2]. Instructing untransformed cells
to take part in development of the tumor organ requires highly regu-
lated cell-cell and cell-stroma communication. Most cells are known
to secrete a number of extracellular vesicles (EVs) that carry signaling
molecules within the nervous system [3]. EVs secreted by tumors are
known to carry RNAs and signaling molecules that alter the fate of re-
ceiving cells [4,5]. An emergingmode of delivery of extracellular signalsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
TheV-ATPase protonpumphasbeen involved in cancer stemcells
maintenance and V-ATPase-high glioblastomas express higher
levels of homeobox genes. Moreover, the V-ATPase has been in-
volved in synaptic vesicles uptake/release and in the modulation
of the microenvironment.
Added value of this study
We show that GBM neurospheres with high levels of V-ATPase
expression secrete large oncosomes (LOs), a type of extracellular
vesicle loaded with oncogenic cargoes. These LOs carry homeo-
box factors and V-ATPase subunit G1 and are able to reprogram
the brain microenvironment toward a pro-tumorigenic state. Fi-
nally, LOs are also found in the circulation of glioma patients and
are poor prognostic factors.
Implications of all the available evidence
A role for V-ATPase in themodification of the surroundingmilieu is
emerging. These data identify a global cell fate change that under-
lies glioma aggressiveness and suggest new entry points for gli-
oma patients' follow-up and therapy.
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formed when a large portion of cellular membranes is shed from the
cell surface during blebbing events [6,7]. GBM secrete a number of ves-
icles carrying a large variety of signals in the form of proteins and RNAs
that can also be recovered from body ﬂuids of patients [8–10]. However,
how EVs, and in particular LOs, reprogram their surroundingmicroenvi-
ronment is poorly known. Importantly, it has been shown that the
genetic and phenotypic intratumor heterogeneity is also reﬂected in
the EVs' repertoire [11]. Indeed EVsmight contribute to glioma cell plas-
ticity and to inﬂuence functional integration of glioma stem cells (GSC)
with other cancer cell populations. In this context, the understanding of
GSC vesiculome could provide novel insights into mechanisms of dis-
ease progression and resistance to therapy.
The vacuolar ATPase (V-ATPase) is a proton pump involved in a
number of acidiﬁcation-dependent processes in the cell in physiological
as well as pathological contexts [12]. In a recent study, we have deter-
mined that V1G1, a subunit of the V-ATPase that is highly expressed
in GBM, plays a functional role in GSC and can be used as an accurate
prognostic marker [13]. In the accompanying study published in this
issue, we show that differences between aggressive GBMs and lower
grades gliomas include not only V1G1 but also a number of other
V-ATPase subunits. We also reveal the existence of a GBM transcrip-
tional proﬁle that, in addition to many V-ATPase subunits, comprises
also high expression of Hox genes resembling that of undifferentiated
embryonic cells (Terrasi et al., this issue) [36]. However, whether such
genes are also able to inﬂuence the tumor surrounding milieu possibly
through EVs is not known.
Therefore, we analyzed GSC derived LOs and their functional effects
in neoplastic and non-neoplastic brain cells to get insights into a novel
V-ATPase role in gliomagenesis.
2. Materials and methods
2.1. Primary, patients-derived or commercial cell cultures
GBM neurospheres (NS, n = 33) were obtained from fresh tumor
tissue of GBM patients as previously described [13]. For LO co-cultureexperiments, recipient primary cells were isolated directly from pa-
tients' non-neoplastic (margins, n = 22) taken outside the tumor
area, or tumor (n = 18) tissues. To conﬁrm tissues histology, a portion
of each sample was snap-frozen and a section was stained with hema-
toxylin and eosin (H&E). All patients were enrolled at the Division of
Neurosurgery and glioma was diagnosed at the Division of Pathology
of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
(Milan, Italy). This study was approved by a local Ethic Committee
(IRB#275/2013) and all patients signed an informed consent.
All cases were reviewed and graded by senior pathologist (SF) ac-
cording to the new classiﬁcation of the World Health Organization
(WHO [14];). To obtain single cell suspensions, tissues underwent enzy-
matic and mechanical dissociation digestion in serum-free media using
the Tumor Dissociation kit (Miltenyi). Then, cells suspensions were
washed twice with HBSS (Gibco-Invitrogen, Thermo Fisher Scientiﬁc,
Waltham,MAUSA) and seeded in NeuroCult (NC)media supplemented
with growth factors (Proliferation Supplement, bFGF and EGF, all from
Voden). Margin cultureswere immunoproﬁled by immunoﬂuorescence
or FACS using the following antibodies: Nestin, Tuji, GFAP, CD11b, O4,
Olig2, CD31 and Vimentin. For FACS analysis, cells were ﬁxed in PFA
2% for 10 min, permeabilized in Triton 0.1% for 10 min and stained
with primary (1:100/1 h) and secondary antibody (1:1000/30 min) at
room temperature (RT). Unstained cells were used as negative control,
whereas cells incubated with immunoglobulin of the same isotype of
the primary antibody were used as isotype control.
LN229 cells were purchased from ATCC (Manassas, VA, USA) and
maintained in RPMI media supplemented with 10% exosome-free FBS
(Exo-FBS, System Biosciences).
2.2. Immunohistochemistry (IHC) in GBM patients' derived orthotopic
mouse model xenograft or in human glioma tissues
Brains frommice inoculatedwith vehicle (controls) or primary GBM
NS characterized by low or high V-ATPase G1 expression were har-
vested at sacriﬁce and formalin-ﬁxed and parafﬁn embedded (FFPE)
as described in the companion study (Terrasi et al., this issue) [36].
Then, hematoxylin and eosin (H&E) staining was performed to conﬁrm
tissue morphology followed by immunohistochemistry for HOXA10
(TA590263, Origen), STEM121 (Y40410, Takara Bio Europe) and
POU3F2 (12137, Cell Signaling). Human tissues were already FFPE
blocks. IHC for V-ATPase G1 (16143-1-AP, Proteintech), Nestin
(MAB1259, R&D Systems), HOXA10, or POU3F2 was performed using
a Ventana Benchmark instrument and the Ultraview DAB or Red Detec-
tion kits as described [13]. For murine samples, slides were pre-
incubated with the Rodent Block M reagent (Biocare Medical), to
block endogenous mouse IgG and non-speciﬁc background, before pri-
mary antibodies. Percentage of positive tumor cells in PDTX tumors
was analyzed using Aperio Digital Pathology slide scanner (Leica
Biosystems, Milan, Italy) and the nuclear algorithm implemented in
ImageScope software (Leica Biosystems) as described [15].
2.3. LO isolation from NS media or patients' sera
LOwere isolated from supernatant of NS (n= 12) at basal condition
(after 24 h of NS culturewith freshmedia), after 10 nMBafA1 treatment
of NS for 24 h, or after siRNA-mediated knockdown of V-ATPase G1 in
NS as described [7]. Brieﬂy, cells and debris were removed by centrifu-
gation at 250 rcf for 5 min followed by 1.000 rcf for 10 min at 4 °C. Fi-
nally, supernatants were collected and concentrated using Amicon
Ultra centrifugal ﬁlter tubes (Millipore). Supernatants were then centri-
fuged at 10.000 rcf for 30 min at 4 °C. Pellets containing LO were then
washedwith 0.2 μm-ﬁltered PBS, resuspended in ﬁltered PBS and stored
at−80 °C before using for functional experiments or RNA/protein ex-
traction. Vesicles concentration and size distribution was analyzed
using Nanosight NS300 (Malvern, Instruments Ltd. Worcestershire,
UK). LO were stored as single aliquots of 20 μl and, for functional
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tration of 3 × 108 LO/ml (which corresponded to a single 20 μl-aliquot).
For controls (mock samples), fresh NC medium was processed as
culturemedia and stored at−80 °C. Fresh patients' sera were processed
immediately after bloodwithdrawal as previously reported [16]. Brieﬂy,
sera were centrifuged at 700 rcf for 15min at 4 °C, after which LO isola-
tion was performed using 500 μl of the supernatant and processed as
described for cell culture media.
2.4. Analysis of LO evagination from NS by confocal microscopy
To investigate LO production from live NS, cells were incubated for
30 min at 37 °C with FM 1–43 FX at 40 uM (ThermoFisher Scientiﬁc).
After twowashes in PBS, NSwere seeded on glass bottomwell (MatTek)
and followed live for 20 min using the gas/humidiﬁcation chamber of
the confocal microscope (TSC5). Images were captured every 5 min
and LO (dimension between 1 and 5 μm)were identiﬁed as evagination
of the plasma membrane.
2.5. Flow cytometry of LO
LO were stained for 20 min at 37 °C with CellTrace Violet (5 μM, in-
tact membrane staining) and SYTO RNASelect (10 μM, RNA staining),
washed twice with ﬁltered PBS and visualized using a FACSCanto II in-
strument (BD Biosciences). As negative control (mock samples), we
used LO isolated from empty NeuroCult media. FlowJo V.10.1 software
(BD Biosciences) was used to analyze data.
2.6. LO internalization
For internalization assays, LO or control were stained with PKH26
dye (Sigma Aldrich) or with FM 1-43 FX at 40 uM (ThermoFisher Scien-
tiﬁc). Brieﬂy, dyes were added to LO pellets for 5 min at RT and the
staining was blocked with 10% BSA in ﬁltered PBS. LO preparations
were thenwashed three times and pelleted at 10.000 rcf for 30min. Re-
cipient cells (primary GBM or margin cells) were seeded on 96-wells
glass bottom plates (MatTek Ashland, MA) at 80% conﬂuence and
stained with the vital dyes CellTrace Violet (5 μM, cytoplasm staining)
and CellsMask (1:1000, cytoplasm and plasma membrane staining)
for 30 min at 37 °C in PBS. Then, cells were rinsed twice with ﬁltered
PBS and fresh medium was added. After 24 h, one aliquot of PKH26-
stained LO or vehicle was added to recipient cells. LO internalization
was evaluated after 6 and 24 h of co-culture in live cells using live con-
focal microscopy and a 63X objective. Leica software tools line proﬁle –
intensity – sort ROI (Leica Microsystems LAS AF 2.6.0.7266) were used
to discriminate LO internalized in recipient cells from LO bound to the
plasma membrane. In particular, for each image the intensity of
the three dyes proﬁles was investigated in 3 z-stacks corresponding to
the cell top, middle and bottom.
2.7. Functional experiments
For evaluation of cell growth after LO co-culture, recipient cells were
seeded in 24 multi-wells plates and let reach 60% of conﬂuence. Then
cultures were stained with CellTrace Violet (5 μM for 20 min at 37 °C)
and one aliquot of LO or vehicle (mock samples) was added per well.
The percentage of divided cells was evaluated as the decrease in
CellTrace Violet ﬂuorescence intensity, whereas the number of cell divi-
sions was analyzed using the FlowJo software tool “proliferation”. Both
analyses were performed at 3, 10 and 17 days after co-culture using
FACS and analyzed by FlowJo V.10.1 software. To assess the effect of
LO on neurospheres generation, primary GBM-derived cultures were
seeded in 48-wells plates in NeuroCult media and observed for
2 weeks. If the culture did not form NS, one LO or vehicle aliquot was
added per well. After 24 h supplements were removed and sphere for-
mation was monitored at 3, 6 and 90 days as previously described [13].For invasion assays, NS with low V-ATPase G1 level (LOLow) were
preincubatedwith LO fromNSwith high or lowV-ATPaseG1 expression
(LOHigh or LOLow) and then embedded in a collagen matrix (C4243;
Sigma Aldrich). Cell spreading through the matrix was monitored up
to 3 days and images were captured every 24 h using a time-lapse mi-
croscope (Eclipse Ti-E, Nikon Instruments; Florence, Italy). The radius
of invasion was calculated as the distance of invaded cells from the
edge of the NS using Volocity software (PerkinElmer, Waltham, MA,
USA). NS clonogenicity assay was previously described [13].
2.8. Electron microscopy (EM) and immunogold staining
For ultrastructural morphology examination, spheroids were ﬁxed
in 2.5% glutaraldehyde, embedded in 2% agar solution, post-ﬁxed in 1%
osmium tetroxide in phosphate buffer, dehydrated and embedded in
epoxy resin. Ultra-thin sections (50–60 nm) were counterstained with
uranyl acetate, lead citrate and observed in a Jeol JEM 1010 (Tokyo,
Japan) transmission electron microscope. Images were then captured
using a FEI Tecnai G2 20 Transmission Electron Microscope. To identify
multivesicular bodies, intracellular images were captured at 1840X
magniﬁcation, whereas to evaluate extracellular vesicles (exosomes,
ectosomes and large oncosomes) presence and production, images of
the extracellular milieu were captured at 5000Xmagniﬁcation. Quanti-
ﬁcation of EVs diameter in TEM images was performed using Volocity
(PerkinElmer Inc., Waltham, MA) software. Brieﬂy, EVs were manually
selectedwith a circular ROI as objects and their diameter wasmeasured
to identify LO (≥1 μm). Then LO number per area of extracellular space
was calculated for each NS type. Isolated LO were prepared for EM fol-
lowing the protocol of Lobb et al. [17] Brieﬂy, 7 μl of samples were
absorbed on glow-discharged carbon-coated formvar nickel grids for
2 min. The drops were then blotted with ﬁlter paper and negatively
stained with 2% uranyl acetate (5 μl) in aqueous suspension for 2 min.
Excess of uranyl was removed by touching the grid with ﬁlter paper
and the grid was dried at RT. Grids were examined at Zeiss LEO 912ab
electron microscope at 80 kv. To evaluate the presence of V-ATPase G1
or of HOXA10 in LO, immunogold labeling was carried out. Few micro-
liters of the sample were absorbed on glow-discharged carbon-coated
formvar nickel grids, blocked in 1% BSA in PBS and incubated with pri-
mary antibody (1:100). After severalwashes in 0.1%BSA in PBS, samples
were incubated for 30 min with goat anti-rabbit IgG conjugated with
10 nm colloidal gold particles (BBInternational), ﬁxed with 1% glutaral-
dehyde, stained with 2% uranyl acetate, and air-dried. Grids were ob-
served with a Zeiss LEO 912 transmission electron microscope. Images
were acquired by a 2 k × 2 k bottom-mounted slow-scan Proscan cam-
era controlled by EsivisionPro 3.2 software. Images were captured at
12.500 and 20.000X magniﬁcation.
2.9. RNA puriﬁcation and genes expression analyses
Total RNA was puriﬁed from cell cultures and large oncosomes (LO)
using Master Pure RNA puriﬁcation kit (Epicentre Biotechnologies,
Illumina; Madison, WI, USA) followed by DNA digestion with DNase I,
Ampliﬁcation Grade (Thermo Fisher Scientiﬁc). In co-culture experi-
ments, mRNA was extracted after 3 or 6 and 90 days after LO supple-
mentation of margins or GBM tumor cells cultures. Then, 300 ng of
DNA-free total RNA from cell cultures were reverse transcribed using
the SuperScript II Reverse Transcriptase and random hexamers (both
from Thermo Fisher Scientiﬁc) in 20 μl or reaction mix. For LO, 100 ng
of DNA-free total RNA were retrotranscribed and preampliﬁed using a
custom PreAmp primers pool, prepared diluting TaqMan assays (listed
in Supplementary Table 8) in 1X TE buffer to a ﬁnal concentration of
0.2.Targets gene expression was quantiﬁed by qPCR using TaqMan as-
says together with the reference genes β2microglobulin and/or 18S
RNA. Genes expression was evaluated by quantitative PCR (qPCR) and
target genes were relatively quantiﬁed on the reference transcripts av-
erage using the 2^(-Delta Ct) formula. Then, targets relative quantities
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(dPCR) analysis, we used the QuantStudio Digital PCR Kit (Thermo
Fisher scientiﬁc) and the absolute amount (copies per μl) of POU3F2
transcript in LO from patients' sera or NS media was quantiﬁed from
25 ng of the previously obtained cDNA. For transcriptomic analysis of
LO-or mock-cocultures (n = 2 pairs), RNA was puriﬁed as before and
RNA integrity was veriﬁed by Agilent Bioanalyzer (Agilent Technolo-
gies). Then samples were processed on a GeneChip Human Gene 2.0
ST Array (Affymetrix, part of Thermo Fisher Scientiﬁcs), as previously
described [18]. Raw data were preprocessed and normalized using the
RobustMulti-array Average (RMA)method implemented in the R pack-
age “Affy”. Expression data were then analyzed using Gene Set Enrich-
ment Analysis (GSEA) module available within Genepattern (http://
software.broadinstitute.org/cancer/software/genepattern/modules/
docs/GSEA/14) using the “gene_set” as permutation type and all other
default parameters. Raw and processed data is deposited in GEO public
database (accession number: GSE120793).
2.10. siRNA transfections
GBM primary cultures were transiently transfected in Optimem
media using Lipofectamine 3000 (both from Invitrogen, Thermo Fisher
Scientiﬁc) and 100 pM of speciﬁc or non-targeting control siRNAs or
esiRNA (all from Sigma Aldrich, St. Louis, MO, USA). The siRNA
SASI_Hs02_00338522was used to silence V-ATPase G1 transcript as de-
scribed [13]. After 5 h, transfection mixture was replaced with standard
culturing media.
2.10.1. Antibodies and reagents
Lysotracker, CellTrace Violet, FM lipophilic styryl (FM 1-43FX) and
SYTO RNASelect dyes were from Life Technologies (Thermo Fisher Sci-
entiﬁc). Acridine Orange was from ImmunoChemistry Technologies
(Bloomington, MN, USA). PropidiumIodure (PI) and Annexin V were
from BD Bioscience (FITC-Annexin V Apoptosis Detection Kit).
Baﬁlomycin A1 (BafA1; sc-201550) was from Santa Cruz Biotechnol-
ogies whereas NH4Cl (254134) was from Sigma Aldrich.
The following primary antibodies were used for immunoﬂuores-
cence, immunoblotting (IB) and ﬂow cytometry (FACS) assays: V-
ATPase G1 (16143-1-AP, Proteintech), Vinculin (V9131, Sigma Aldrich),
Tsg101 (14497-1-AP, Proteintech), Ago2 (10686-1-AP, Proteintech),
Clathrin (ab23440, Abcam), CD63 (sc-15363, Santa Cruz), CD9 (IB:
10626D, Thermo Fisher; FACS: 130-103-988, Miltenyi), CD81 (130-
107-982, Miltenyi), Calnexin (ab31290, Abcam), Nestin (MAB 1259,
R&D), Tuji (T3952, Sigma Aldrich), GFAP (G9269, Sigma Aldrich),
CD11b (20991-1-AP, Proteintech), O4 (O7139, Sigma Aldrich), Olig2
(AV32753, Sigma Aldrich), CD31 (ab28364, Abcam), Vimentin (130-
106-369, Miltenyi), POU3F2 (12137, Cell Signaling), HOXA10
(TA590263, Origen), HOXA7 (ab211521, Abcam), V-ATPase G2
(25316-1-AP, Proteintech), ARF6 (6ARF01, ThermoFisher Scientiﬁc),
and GRP78 (3177, Cell Signaling).
2.11. Immunoﬂuorescence
For immunoﬂuorescence experiments, monolayer cultures were
grownon cover-glasseswhereasNSwere cytospinnedon charged slides
for 3min at 900 rpm (ThermoScientiﬁc,Waltham,MA, USA). Cellswere
ﬁxed in PFA 4% for 15 (monolayer cultures) or 30 min (NS), quenched
for green auto-ﬂuorescence using glycine 20 mM for 20 min and then
permeabilized with Triton 0.5% for 30 min at room temperature. Then,
samples were saturated with BSA 10% for 1 h at RT. Primary antibodies
(1:100 in PBS-BSA 10%) were incubated overnight at 4 °C whereas sec-
ondary antibodies (1:1000) were incubated for 1 h at room tempera-
ture. Finally, nuclei were stained with Hoechst 3342 (Cell Signaling)
for 5 min at RT and slides were mounted using the Prolong reagent
(ThemoFisher Scientiﬁc). For negative controls, one slide per target pro-
tein was incubated with all reagents but the primary antibody. Confocalimageswere generatedwith a Leica TCS SP5 Confocalmicroscope (Leica
Microsystems, Milan, Italy) with a magniﬁcation of 40X or 63X, and z-
stack images were captured every 0.46 μm. Fluorescence quantiﬁcation
was calculated on full cell stacks after setting the threshold on control
samples, and the mean intensity of the ﬂuorochrome was calculated
using ImageJ software.
2.12. Immunoblotting
Cells and LO protein extracts were prepared in RIPA buffer supple-
mentedwith phosphatase and protease inhibitors (Roche). For LOprep-
arations, 3% SDS was added as pretreatment. After lysis, samples were
sonicated ﬁve times on ice (Bioruptor Plus sonication device,
Diagenode), pelleted at 15.000 rcf to remove debris and quantiﬁed
using microBCA kit (Thermo Fisher Scientiﬁc). Proteins (40 μg) were
boiled for 5 min at 95° (in non-reducing condition for CD63 detection),
resolved by SDS-PAGE, transferred to nitrocellulosemembrane, blocked
in 5% not-fat powdered milk in PBS-T (1% Tween-20) and probed with
antibodies. Proteins bands were then visualized using the Amersham
ECL Prime Western Blotting Detection Reagent (GE Healthcare) and
the LAS-3000 imager (Fujiﬁlm).
2.13. Statistical analyses
Data from functional experimentswere imported in GraphPad Prism
software (La Jolla, CA, USA) and analyzed using the non-parametric
Mann-Whitney U and Kruskal-Wallis tests for two-sample or more
than two-sample comparisons, respectively. Data are presented as
mean ± SEM and experiments were performed at least three times
and in technical duplicate unless otherwise speciﬁed. In particular, ex-
periments involving patients' derived NS were performed with ﬁve
V1G1High- and ﬁve V1G1Low- NS in triplicate. LO were isolated from 12
NS, equally distributed for V-ATPase G1 expression for LO co-cultures
with GBM recipient cells (n = 10), we performed biological triplicate
for each patients' sample, whereas non-neoplastic margin cultures (n
= 20) were analyzed using a single technical replicate because of the
limited material available. Categorical data were analyzed using chi
square test. P values b.05 were considered statistically signiﬁcant if
not otherwise speciﬁed.
3. Results
3.1. GBM with elevated V-ATPase G1 expression display upregulation of
homeobox genes in vivo
In the accompanying paper we determined that GBM neurospheres
with elevated V-ATPase G1 (V1G1HighNS)were also enriched for the ho-
meobox genes HOXA7, HOXA10 and POU3F2 (Terrasi et al. in this issue)
[13,36]. Therefore we analyzed these homeobox proteins in GBM
patients-derived orthotopic xenografts generated by V1G1Low or V1G1-
HighNSand in human GBM tissues characterized for V1G1 expression.
Overexpression of homeobox genes in V1G1HIGH NS was also preserved
in vivo (Fig. 1a and Fig. S1a). In fact, orthotopic brain tumors generated
from V1G1HIGHNS contained more HOXA10- or POU3F2-positive cells
(p = 0.006 and p = 0.0012, respectively; Fig. 1b). Control brains from
mice not injected with GBM NS were negative for all markers
(Fig. S1b). These data conﬁrm that upregulation of homeobox genes is
a signature that deﬁnes V1G1-high gliomas.
3.2. NS reprogram their microenvironment via large oncosomes loaded
with V-ATPase V1G1 and homeobox proteins
In the companion study (Terrasi et al., this issue) [36] in silico anal-
ysis of pathways associated to the V-ATPase-GBM-like phenotype iden-
tiﬁed cell-cell signaling, besides hox genes overexpression. This result,
together with current knowledge regarding the importance of glioma
Fig. 1. V-ATPaseHIGH tumors express higher levels of homeobox genes in vivo also at their periphery. a,b) Expression of the homeodomain-containing genes HOXA10 and POU3F2 was
evaluated by immunohistochemistry (IHC) in orthotopic gliomas generated by intracranial injection of NS with different V-ATPase G1 levels. Tissue morphology was evaluated by
hematoxylin and eosin staining (H&E), whereas expression of HOXA10 or POU3F2 in tumor cells was assessed by double IHC using antibodies speciﬁc for human cells (STEM121) and
the homeodomain protein. a) Representative images (see also Supplemental Fig. S1a). Dotted line = tumor border. HOXA10 and POU3F2 scoring was performed using a digital
algorithm for nuclear staining and expressed as the percentage of positive tumor nuclei within the total tumor cell population (count mask in a; b, quantiﬁcation; n = 7). ***, p =
0·0006; **, p = 0·001 (Mann-Whitney U test). c) V-ATPaseG1, HOXA10, and POU3F2 were detected by IHC in human GBMs, in surrounding non-neoplastic parenchyma (margin),
and at distant sites (see also Supplemental Fig. S1c). Absence of neoplastic cells was determined by morphological (H&E) and immunophenotype examination (negative Nestin
staining). Scale bars, 200 μm. d) Quantiﬁcation of HOXA10, POU3F2, and ATP6V1G1 and G2 transcripts in the indicated types of brain parenchyma (tumor, margin, distant site)
isolated by laser-assisted microdissection (n = 8 patients). *, p = 0·01; #, p = 0·03; §, p = 0·02 (Mann-Whitney U test). RQ, relative quantity. In b and d, data are presented as box
plots with whiskers indicating the minimal and maximal values. Each sample is a dot.
229I. Bertolini et al. / EBioMedicine 41 (2019) 225–235stem cells in inﬂuencing the non-neoplastic parenchyma, prompted us
to examine expression of V-ATPase and homeobox proteins at tumor
margins (deﬁned as non-neoplastic areas in close proximity to the
tumor), as well as at distant brain parenchyma sites, in a subset of
GBM patients with elevated expression of V-ATPase G1 (n = 11;
Fig. 1c and Fig. S1c). Tumor margins appeared signiﬁcantly impacted
by tumor proximity in that they displayed an intermediate level of
V-ATPase and homeobox expression between that shown by glioma
and normal (distant) brain tissues (Fig. 1c,d and Fig. S1c). We also
evaluated Nestin, amarker of GBM cells, to verify that marginswere de-
void of tumor cells. Indeed, therewas no difference in Nestin expression
between the two types of non-neoplastic brain tissue (Fig. 1c and
Fig. S1d).
Intermediate expression of V-ATPase and homeobox genes in non-
neoplastic areas proximal to tumor suggests that GBM cells might de-
liver tumor-associated cargoes to nearby cells. Therefore, we analyzed
whether GBM NS secrete EVs. Electron microscopy revealed that GBM
NS generated and secreted a large number of EVs of different sizes
(Fig. 2a and Fig. S2a). We focused our attention on large oncosomes
(LO) because of their established role in delivering cargoes, including
proteins, and their supposed tumor origins [7]. We isolated LO from
NS culturemedium (Fig. 2b) and assayed them for expression of speciﬁc
protein markers (Fig. 2c) or for the presence of speciﬁc RNA (Fig. S2b).
Next, we veriﬁed that puriﬁed LO from either NS V1G1Low or V1G1High
were similarly internalized by recipient cells (Fig. 2d and Fig. S2c,d) of
neoplastic or non-neoplastic (brain margins; Fig. S3a,b) histology to
prove that they were functional. Then, we hypothesized that these ves-
icles were different in their contents with respect to V-ATPase G1 levels
on the NS from which they originated. LO from V1G1High NS (LOHigh)
contained more homeobox transcripts than LO generated by V1G1Low
NS (LOLow; Fig. 2e). Interestingly, LOHigh harbored higher amounts of
V-ATPase G1 mRNA (Fig. 2e) and protein (Fig. 2f) than LOLow. Upon
co-culture of LOHigh with recipient cells for 24 or 48 h (Fig. S2c), homeo-
box and V1G1 genes were overexpressed by recipient cells at themRNAand protein level (Fig. 2g,h and Fig. S4a). This effect was not seen in cul-
tures supplemented with LOLow (Fig. 2g and Fig. S4a,b) and it was not
due to lower content of LO fromNSV1G1Low respect to NS V1G1High cul-
tures (Fig. S4c,d). More interestingly, the molecular cargoes were
expressed by recipient cultures up to 90 days from the LO supplementa-
tion (Fig. 2i).
Froma functional point-of-view, supplementation of the cultureme-
diumwith LOHigh increased the survival and proliferative activity of cul-
tured non-neoplastic cells (derived from margin tissues; Fig. 3a–c and
Fig. S5a,b) and glioma cells (LN229; Fig. S5c). When primary non-
sphere-forming glioma cells were co-cultured with LOHigh, they were
induced to form NS, and their immunophenotype was altered as evi-
denced by decreased expression of GFAP protein (Fig. 3d). Finally, NS
motility increased upon supplementationwith LOHigh (Fig. 3e). Remark-
ably, a single supplementation with LOHigh was sufﬁcient to induce
primary glioma cultures to form long-lived NS (Fig. 3f). Both NSmotility
and clonogenicitywas not affected by co-culturewith LOLow (Fig. S5d,e).
The longevity of such NS correlated with HOX transcript levels
measured on Day 6 from the start of co-culture (Fig. 3g); also, LOHigh-
treated recipient cells upregulated expression of the HOXA10-
responsive gene CDKN1A (Fig. S5f) [19], suggesting that these effects
were related to transfer of HOX-genes.
Given this functional reprogramming, we examined the tran-
scriptome of primary non-sphere-forming glioma cells co-cultured for
6 days with empty medium (mock) or with medium containing LOHigh.
Gene set enrichment analysis (GSEA) revealed that LO-supplemented
cultures activated a number of cancer-related pathways, including
those involved in glioma V-ATPase-related signaling (Notch, mTOR,
and lysosomal transport) [20], as well as cell proliferation and cell tran-
scription programs (Fig. 3h and Table S1). Finally, 10 among the top
genes identiﬁed in the transcriptomic analysis as differentially upregu-
lated in LO treated samples (FC N 2, p b 0.01 byWilcoxonmatched paires
test; Table S2) were analyzed by qPCR in ﬁve cultures of non-sphere-
forming glioma cells (Fig. S5 g). We could validate overexpression of
Fig. 2. Large oncosomes from GBM NS carry and deliver V-ATPaseG1 and homeodomain transcripts to recipient cells. a) Electron microscopy (EM) of a cell within GBM NS shows the
presence of abundant extracellular vesicles. b) Representative EM image of large oncosomes (LO) puriﬁed from NS medium. Scale bar, 500 nm. c) Presence/absence of protein markers
speciﬁc for LO was determined by western blotting and compared with that in corresponding cell lysates (NS). MW, molecular weight. d) Puriﬁed LO or empty medium (mock) was
stained with PKH26. Internalization of LO by recipient cells (LN229 cells) was visualized by confocal microscopy. The CellTrace dye was used to visualize the cell cytoplasm. Scale bar,
50 μm. e) The indicated transcripts in LO derived from NS with high (V1G1HIGH) or low (V1G1LOW) levels of V-ATPaseG1 were evaluated by qPCR. Bars, mean ± SEM. f) LO from NS
with high (i) or low (ii) V-ATPase G1 were analyzed for V-ATPase G1 expression using immunogold labeling. Scale bar, 500 nm. g,h) Expression of the indicated transcripts (RQ; g;
bars, mean ± SEM) or proteins (h; see also Supplemental Fig. S3b) in recipient cells (non-sphere forming primary glioma cultures) was evaluated after co-culture with LO from NS
with high (+LOHigh) or low (+LOLow) V-ATPase G1 expression, or with empty medium (mock). Scale bar, 50 μm. In g, the dotted line represents transcript level detected in ViG1High
neurospheres (NS). i) Expression of homeodomain genes or of V-ATPase G1 in recipient cells (non-sphere forming primary glioma cultures) was evaluated after 6 or 90 days of co-
culture with LOHigh. RQ, relative quantity. Bars, mean ± SEM.
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and of transcripts involved in glioma tumorigenesis or drug resistance
such as TTLL7 [21] and RFC5 [22]. Furthermore we conﬁrmed upregula-
tion in LO-supplemented cultures of genes involved in cancer cell prolif-
eration, such as BOC[23] and invasion, such as TCTN2 [24] or NFIB [25].
This experiment lends further support to the hypothesis that LOderived
from V1G1HighNS induce extensive transcriptional changes in recipient
cells, thereby promoting tumor growth.3.3. LO derived from GBM patients carry V-ATPaseG1 and homeobox
proteins
Next, we asked whether LO were also present in the circulation of
glioma patients before surgery, and whether their molecular content
reﬂected our observations regarding GBM NS. Not only were LO iso-
lated from the serum of glioma patients (n = 28; Fig. 4a), they
were also functional (i.e., were internalized by recipient cells;
Fig. 3. LOHigh reprograms recipient cells to activate tumorigenic pathways. a–c) Primarynon-neoplasticmarginswere stainedwith the vital dye Paciﬁc Blue and cellswere co-culturedwith
the indicated LO or emptymedium (mock). Cell viability and proliferationweremonitored by bright ﬁeldmicroscopy after 3, 10, and 17days (a, representative images at day 10) and FACS
analysis (b, c; see also Supplemental Fig. 4a, b). Scale bar, 100 μm. d) Primary non-sphere-forming glioma cultures were supplemented with the indicated LO or empty medium (mock),
and their morphology and immunophenotype were monitored after 3 and 6 days. Left, representative images of recipient cells stained with markers of differentiated glia (GFAP) and
ﬁlamentous actin (Phalloidin). Right, quantiﬁcation of tumor spheres formed after co-culture at the indicated times. §, p b 0·0001 (Anova with Tukey's post-test). e) NS with low levels
of V-ATPase G1 (poorly invasive) were co-cultured with LOHigh, LOLow or empty medium (mock), and the spread of tumor cells within the collagen matrix was monitored for 3 days by
time-lapse microscopy. Left, representative images of NS at the time of seeding (full line) and after spreading (dotted line). Right, quantiﬁcation of the area of collagen matrix invasion.
**, p = 0·008 (Anova with Tukey's post-test). See also Supplementary Fig. 3d. f) The presence and viability of tumor spheres formed from primary, non-sphere-forming glioma cells
co-cultured with the indicated LOs or empty medium (mock) were monitored and quantiﬁed (left panel) for up to 90 days. *, p = 0·036; #, p b 0·0001 (Anova with Tukey's post-
test). g) The indicated transcript was quantiﬁed by qPCR in primary, non-sphere-forming recipient glioma cells after co-culture with LOHigh. Transcripts expression was then compared
between cultures that were alive after 90 days from LO supplementation and cultures that rapidly extinguished (before day 21). RQ, relative quantity. h) GSEA enrichment score
curves. Gene set enrichment analysis (GSEA) was performed using the transcriptome obtained from primary, non-sphere-forming glioma cells co-cultured with LOHigh or empty
medium. The name of the enriched plots for pathways (KEGG) or GO term is indicated on each panel. The “difference of means” metric was used to rank genes according to their
correlation with the LO- (red) or mock-supplemented (blue) phenotype. NES, normalized enrichment score; adj p value, p value adjusted for false-discovery rate. In panels c-g, data
are presented as mean ± SEM.
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Fig. 4. Circulating LO from GBM patients carry V-ATPase G1 and Homeodomain proteins. a) LO puriﬁed from GBM patient sera were analyzed by electron microscopy. Representative
images from two different patients are shown. Scale bar, 500 nm. b) Patient-derived LO (stained with PKH26) are internalized by primary non-neoplastic margin cultures (stained
with CellTrace vital dye). Scale bars, 10 μm. c) Protein markers were analyzed by western blotting of LO puriﬁed from the indicated patient serum. See also Supplementary Fig. S5a.
d,e) qPCR analysis of ATP6V1G1 (D) or POU3F2 (E) transcripts in circulating LO from patients with IDH-mutated (n = 8) or wild-type (n = 3) LGG (LGG/IDHmut and LGG/IDHwt,
respectively), or GBM (n = 17) (left graphs), and in GBM patients according to survival status (right graphs). Each dot represents a single sample and data are expressed as the mean
± SEM. RQ, relative quantity. f) A ROC curve with Youden's statistic was generated to identify the cut-off (J index) for POU3F2 expression in LO from LGG/IDHmut and GBM patients
that best discriminates the diseases. g) LGG and GBM patients were sorted into POU3F2-Low and -High categories according to the ROC-generated cut-off, and their frequencies within
the two groups were analyzed. *, p = 0·017 (Chi-square test). Bars indicate the number of patients per group. h) Time-to-progression in LGG patients categorized as POU3F2-Low or
High was analyzed using Kaplan-Meier curves and the Log-Rank test.
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GRP78; Fig. 4c; Fig. S6a) and homeobox genes (Fig. 4c).
Regarding their molecular cargoes, ATP6V1G1 transcript was higher
in GBM patients-derived LO than in LGG, and was elevated in GBM pa-
tients who died of disease during follow-up (mean survival time:
10.6 months; Fig. 4d). Expression of POU3F2 mRNA was higher in
LGG/IDHwt than in LGG/IDHmut, as well as being upregulated in GBM.
POU3F2 was also high among GBM patients who died of disease
(Fig. 4e). To conﬁrm the qPCR data and to translate those observations
into clinically meaningful markers, we measured expression of
POU3F2 in patient-derived LO using digital PCR (Supplemental
Fig. S6b). Interestingly, the value of POU3F2 expression that best dis-
criminated LGG/IDHmut from GBM cases (corresponding to 11.1 cop-
ies/μl) (Fig. 4f) classiﬁed LGG/IDHwt cases alongside GBM (Fig. 4g)and it was also predictive of shorter disease-free survival time in LGG
patients (p = 0.01; Fig. 4h). These data, though preliminary, show
that aggressive gliomas actively secrete LO loaded with V1G1 and
POU3F2 oncogenic cargoes into the circulation, suggesting the possibil-
ity of using these markers for staging or follow-up purposes.
3.4. The molecular content and biological activity of LO are sensitive to
impairment of V-ATPase pumps in NS
Finally, to provide a preliminary rational for therapeutic interven-
tion, we asked whether the molecular content and functional effects
of LO were modulated by impairment of V-ATPase in NS.
Treatment with the V-ATPase inhibitor Baﬁlomycin A1 (BafA1;
Fig. 5a), or transient silencing of V1G1 by siRNA (Fig. 5b), decreased
Fig. 5. Treatment of NS with Baﬁlomycin A1 reduces both LO content and biological effects. a,b) NS were treated with 5 nM Baﬁlomycin A1 (BafA1; a) for 24 h, or with speciﬁc siRNA
(b) targeting HOXA7 or V-ATPase G1 (V1G1) or non-speciﬁc molecule (Ctrl) for 48 h. Then the protein content of the cytoplasmic and nuclear fractions (a) or whole cell lysates
(b) were examined by western blotting. Laminin A/C and Vinculin were used as loading controls for the nuclear and cytoplasmic/total fractions, respectively. c) Representative EM
images showing NS treated with 5 nM BafA1 or with siRNA targeting V-ATPase G1. Scale bar, 1 μm. d) The indicated transcripts in NS or in LO were analyzed after treatment with a
siRNA targeting V-ATPase G1 (V1G1), or mock (Ctrl). Expression of targets in samples treated with mock siRNA (Ctrl) was set as 1 (dotted red line). Bars, mean ± SEM. e) LO from NS
with low or high V-ATPase G1 expression, or from BafA1-treated NS, were analyzed by western blotting. Cell lysates (CL) were used as a control. f) LO from BafA1- (LO-BafA1) or
vehicle-treated (LO-Ctrl) NS were stained with PKH26 and incubated with recipient cells (LN229 stained with CellTrace), and LO internalization was monitored for up to 24 h. Right,
quantiﬁcation of LO-positive cells. Scale bar, 50 μm. ***, p b 0·0001 (Mann-Whitney U test). Each dot represents a sample and bars indicate mean ± SEM. g) Recipient cells (primary,
non-neoplastic margin) were stained with CellTrace Violet and co-cultured with empty medium (mock), LO-BafA1, or LO-Ctrl for 10 days. Then, cells were harvested and analyzed by
ﬂow cytometry. Left, histogram showing generational peaks, which represent successive cell divisions. Right, percentage of divided cells in each group. **, p = 0·008; *, p = 0·01
(Mann-Whitney U test). Bars, mean ± SEM. h, i) Homeobox genes in recipient cells (non-sphere forming primary glioma cultures) co-cultured with LO-BafA1 were examined by qPCR
(h) or immunoﬂuorescence analysis. For qPCR experiments, the LO-Ctrl for each target was set as 1. Scale bar, 50 μm. Bars, mean ± SEM (n = 6). j) Primary, non-sphere forming
glioma cells were co-cultured with empty medium (Mock), LO-Ctrl, or LO-BafA1, and their ability to generate NS was monitored for up to 6 days. Right, number of spheres formed per
culture (n = 3; dots, mean ± SEM). Scale bar, 10 μm. §, LO-BafA1 vs. LO-Ctrl, p b 0·01; #, Mock vs. LO-Ctrl, p b 0·001; *, LO-BafA1 vs. LO-Ctrl and Mock vs. LO-Ctrl, p b 0·001
(Kruskal-Wallis test with Dunn's post-test).
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tion (Fig. 5a,b). Next, we analyzed whether these treatments altered LO
formation, molecular content, and biological function. LO production by
NS was not affected by either BafA1 treatment or V1G1 knockdown
(Fig. 5c and S4c,d). Besides reducing transcript levels in NS, silencing
of V1G1 decreased its messenger RNA together with POU3F2 andHOXA10mRNAs in NS and LO (Fig. 5d). These data were conﬁrmed at
the protein level (Fig. 5e). From a functional point-of-view, uptake of
LO from BafA1-treated NS (LO-BafA1) by recipient cells was less effec-
tive than that by control cells (Fig. 5f). Moreover, LO-BafA1 were not
able to promote cell growth in non-neoplastic margins (Fig. 5g) and
did not upregulate homeobox transcripts in recipient cells (Fig. 5h,i).
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sphere formation (Fig. 5j).
To test whether the observed effects of V-ATPase impairment on ex-
pression of homeobox genes were speciﬁc for V-ATPase activity or re-
lated to lysosomal dysfunction, we treated LO-forming NS with
ammonium chloride (NH4Cl), which neutralizes lysosomal pH. Expo-
sure of NS to 50 mMNH4Cl reduced intracellular and lysosomal acidiﬁ-
cation in a manner similar to BafA1 (Fig. S7a,b). Interestingly, NH4Cl
partially reduced the clonogenicity of primary GBM cultures and NS in-
vasiveness (Fig. S7c and d, respectively) without affecting NS viability
(Fig. S7e). However, treatment of NS with NH4Cl did not alter expres-
sion of homeobox genes (Fig. S7f). These results suggest that
V-ATPase activity, rather than lysosomal function, is responsible for
cell-cell signaling in GBM stem cells.
4. Discussion
In this study we show that highly tumorigenic glioma stem cells
secrete in their microenvironment large oncosomes, a type of tumor-
speciﬁc EVs loaded with the homeobox genes POU3F2 and HOXA10,
and with the V-ATPase subunit G1. LOs are transferred to both
neoplastic and non-neoplastic recipient cells, thus mediating their
reprogramming toward an oncogenic state activating proliferative and
motility pathways.
Remarkably, LOs loaded with V1G1 and POU3F2were present in the
circulation of glioma patients, and their levels increased with tumor
grade or in patients with a poorer outcome. Based on elevated
POU3F2 levels in LO of glioma patients, we were able to sort out
IDHwt lower-grade glioma and GBM from IDHmut cases, and we
found that the same cut-off is also prognostic for lower-grade glioma
patients in term of disease progression.
Finally, impairment of V-ATPase activity in NS had a marked effect
on LO content and abolished their oncogenic effect on recipient cells.
This suggests that the pump is required for delivery of oncogenic sig-
nals, carried by LO, to the tumor microenvironment. Besides providing
novel insights in glioma progression, our study provides preliminary
data for potential non-invasive biomarkers useful for stratiﬁcation and
follow-up of LGG patients.
In a companion study (Terrasi et al., this issue) [36] we show that al-
ternative expression of V-ATPase subunits stratiﬁes the heterogeneous
class of LGG/IDHwt and identiﬁes the caseswithGBM-like prognosis. In-
terestingly, the GBM-like pump signature, deﬁned as over-expression of
subunit V1G1 over V1G2, of V0A2 over V0A1 and down-regulation of
V1C1, associates with the hox genes and with cell-cell communication
signatures.
Using primary neurospheres cultures we conﬁrmed that Hox genes
are more expressed in cells with the GBM-like pump (Terrasi et al.,
this issue) [36]. Here we extend this information showing that
V-ATPase G1, HOXA10 and POU3F2 are found in vivo in the tumor sur-
rounding milieu of GBM. The proposed mechanism is the delivery of
these factors through large oncosomes shed from GBM stem-like cells
to the microenvironment. In support of this, we show that V-ATPase
G1 protein is present in LO secreted by GBM-NS and that homeodomain
proteins and V1G1 are present also in LO found in the circulation of gli-
oma patients.
EVs play important roles in brain tumors. In glioma, EVs were ﬁrstly
described as transporters of the oncogene EGFRvIII molecule [8].
Besides mediating cell-cell communications by carrying signaling
molecules and nucleic acids, EVs recapture intratumor heterogeneity
and glioma stem cells hierarchy. Furthermore, EVs are proposed to be
partly responsible for the molecular plasticity exhibited by glioma
stem cells, as well as to participate in the switching from a
transcriptomic subtype to another [11].
Among EVs, LO have been previously described in metastatic pros-
tate cancer [6], in which they are internalized by tumor cells as well as
by the surrounding stroma. Consistent to our results, LO were alsofound in the circulation of prostate cancer patients and their abundance
predicted disease progression.
Monitoring of disease progression and therapeutic responses after
resection in GBM patients is currently achieved by serial neurological
examination andMRI analyses. This procedure avoidsmultiple brain bi-
opsies that are highly invasive and impractical in the routine. Therefore,
detection of recurrence is limited by the resolution of the MRI (about
2–3 mm). Moreover, therapeutic protocols for GBM patients are based
on radiation with concurrent chemotherapy [26]. This often results in
a phenomenon called pseudoprogression, which mimics real tumor
progression on MRI [27] and makes disease monitoring more time
consuming.
In light of such limitations, there is a clear clinical need for novel di-
agnostic tools that would allow timely and accurate detection of recur-
rence. Together, our and previous data on EVs detection as a way to
predict disease status, support the use of LO as a potential circulating
biomarker also in gliomapatients. Indeed, LOwere described to be char-
acteristic ofmetastatic cancer cells that are though to drive tumor recur-
rence [6,7]. Moreover, LO should be more accurate in tumormonitoring
than EVs because there are mainly released by neoplastic cells [7,8], al-
though it has been reported that large EVs were also detected in the su-
pernatant of normal dendritic cells [28]. Therefore the presence and
detection of speciﬁc tumor-marker in circulating LO rather than stan-
dard EV markers is likely to be key in determining whether they origi-
nate from the cancer compartment [29].
Previous reports showed that V-ATPase could govern cell-cell and
tumor microenvironment communication [30,31]. Moreover, a role for
V-ATPase in regulating EVs production and uptake has been docu-
mented in both non-mammalian [32] and mammalian organisms. V-
ATPase subunits V1B1 and B2 have been described in urinary EVs in
human distal renal tubular acidosis disease [33], whereas V-ATPase
V1E1 was detected in EVs of metastatic cells of different origins [34].
Our data are in line with these reports and expand current knowl-
edge about V-ATPase involvement in human cancers, by strengthening
the connection between speciﬁc expression of an oncogenic pump
and presence of cancer stem-like cells [12,13,35]. From a clinical
stand-point, such signature is a predictor of an aggressive disease and
of short progression-free survival.
Our studies collectively highlight a strong connection between
V-ATPase and stem cell activity in cancer (Terrasi et al., this issue)
[13,36]. We envisage that GSC might select speciﬁc V-ATPase and Hox
factors delivered by LOs to reprogram non-cell-autonomously their
microenvironment toward a pro-tumorigenic state. Our novel under-
standing of how tumor cells have learned to inﬂuence and instruct the
non-neoplastic milieu will be crucial to develop future therapeutic at-
tempt to block tumor invasion, as well as to overcome resistance to
therapy. Overall, this study paves the way toward the use of GBM LOs
as a treatment targets as well as diagnostic markers.
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